HAI ROBOTICS to Debut Local Team, Present ACR Systems at SITL 2022
HAI ROBOTICS will display its Autonomous Case-handling Robot (ACR) systems in Europe at the upcoming Transport and Logistics Innovation Week (SITL) 2022 in Paris from Apr. 5-8, an event it sees as the launchpad into more European countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005462/en/
HAI ROBOTICS to present ACR systems at SITL 2022 in Paris. (Photo: Business Wire)
SITL 2022 will also mark the debut of the company's local European team.
Considered a disruptive innovator, HAI ROBOTICS is committed to spearheading the future of warehouse automation, with a flexible, easily deployable and cost-effective solution that will massively increase supply chain efficiency in Europe.
Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has expanded its presence quickly into several countries, such as France, Germany, Spain, Italy, the Benelux and the U.K.
It has quickly set up a local team, most of whom are industrial veterans.
Peter Guan, HAI ROBOTICS European General Manager, said HAI Robotics "is dedicated to hiring local top talent in each of the European key regions."
"The company has already employed the services of several native country managers with proven track records in the logistics automation industry. We keep searching for more local talent that can increase the level of our service and support," Mr Guan said.
"We are gearing up to do more exhibitions in Europe," he added.
An expert in building up, structuring and swiftly growing the European business of international companies that want to break into the market, Mr Guan used to be the sales & marketing director at Hikvision for more than ten years.
At SITL 2022, Mr Guan will be joined by Kai Ramadhin, VP of Sales & Marketing Europe, and Thierry Hennebiq, Country Manager France. Both were newly joined.
With more than 20 years of experience in the logistics market, Mr Ramadhin had previously worked with the Dutch corporation Van Riet Material Handling Systems as both interim CEO and the Director of Sales and Marketing.
With more than 10 years of experience in the intralogistics industry, Mr Hennebiq had previously fulfilled roles at the top system integrators in this industry including TGW, Dematic and Vanderlande.
The Better Fit
Compared with existing, especially traditional, warehouse automation solutions, HAI ROBOTICS believe its ACR systems are a better fit for European customers.
Take France, where SITL 2022 convenes, for example. Mr Hennebiq said "huge demand is observed," given the growing demand for logistic services.
"We think our ACR solution can give logistic service suppliers everything they need to optimize their warehouses for massively increased throughput and efficiency," he said.
Mr Ramadhin said HAI ROBOTICS' target industries include mainly 3PL, retail & e-commerce, fashion and FMCG. "Our ACR solution is catered to handle products in these markets."
Compared to logistic service suppliers employing a traditional human labor force, Mr Ramadhin said the ACR systems can "exponentially increase operational efficiency," whilst requiring less time to implement and being more cost-effective than traditional automation solutions.
"HAI ROBOTICS solution provides more flexibility in term of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive," he said.
Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.
Since its foray into Europe last year, HAI ROBOTICS' presence has been expanding swiftly in the local warehousing logistics sector.
It has paired up with France-based global logistics solutions engineering company Savoye and has inked a strategic partnership with Greece's market leader in intralogistics Voyatzoglou Systems.
At a time when e-commerce booms, the company's ACR solution was deployed at a Micro-Fulfillment Center in Europe, significantly improving the last-mile delivery.
"We aim to provide our customers with high quality service and support, both through our own regional teams, as well as our robust network of installation and service partners," Mr Ramadhin said.
To see HAI ROBOTICS's ACR systems live, please visit booth K81, Paris - Nord Villepinte - Hall 6, during SITL 2022.
ABOUT HAI ROBOTICS
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom